Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for THYMOGLOBULIN
- PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity
- Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome
- CyFluATG in Lower Risk MDS
- Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matche
- PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM
- Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation
- A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
- Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
- Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies
- Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation
- HCT Using Treosulfan for Bone Marrow Failure Diseases (BMT CTN 1904)
- Outcomes of Patients After Allo-HSCT With Decitabine and NAC
- Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
- Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.
- Selective CD28 Blockade in Renal Transplant Recipients
- Methods of T Cell Depletion Trial (MoTD)
- Multicenter, Randomized, Open-Label Study to Evaluate AT-1501 in Patients Undergoing Kidney Transplant
- Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation
- Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
- Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation
- PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients
- Haploidentical HCT for Severe Aplastic Anemia
- Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
- Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
- PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
- Low Dose Treosulfan Based Conditioning Regimen in HSCT for Nijmegen Breakage Syndrome
- Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
- rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)
- Low Dose Antithymocyte Globulin (ATG) to Delay or Prevent Progression to Stage 3 T1D
- Stem Cell Transplantation in Crohn's Disease
- ATG Plus PTCy vs ATG for CGVHD Prophylaxis
- Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
- Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
- Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia
- Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
- Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
- TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
- Autologous Transplant To End NMO Spectrum Disorder
- Veloxis de Novo Kidney Transplant ECSWD
- Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA
- Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
- Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia
- Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
- Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection
- Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus
- ATG-F VS ATG for the Prevention of GVHD
- Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
- Conditioning SCID Infants Diagnosed Early
- Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Cardiac Safe Transplants for Systemic Sclerosis
- HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis
- CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
- Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation
- Maximizing Outcome of Multiple Sclerosis Transplantation
- Budesonide for Liver Transplant Immune Suppression
- The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients
- Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507)
- A Blood Stem Cell Transplant for Sickle Cell Disease
- Autologous Stem Cell Transplant for Crohn's Disease
- Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)
- Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin
- Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes
- Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
- Efficacy and Safety of Rabbit Antithymocyte Globulin 3mg/kg in Kidney Transplant Patients Under Steroid-free and CNI Minimization Maintenance Immunosuppressive Regimen
- Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients
- ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors
- Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.
- Influence of Thymoglobuline on Phenotypic and Functional Profiles of B Lymphocytes in Renal Transplant Recipients
- Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
- Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease
- Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients
- Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia
- NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
- Omental Islet Transplant
- HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen
- The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia
- Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients
- Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
- Allogeneic Stem Cell Transplantation for Children With CML
- Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients
- Autologous Stem Cell Transplant for Refractory Crohn's Disease
- Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
- Allogeneic Stem Cell Transplantationin Relapsed Hematological Malignancy: Early GVHD Prophylaxis
- Diabetes Islet Preservation Immune Treatment
- MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
- A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation
- Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
- Minimal Islet Transplant at Diabetes Onset
- Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
- Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma
- Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant
- Thymoglobulin Induction Therapy in Kidney Transplantation (6mg/kg vs 4mg/kg)
- Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
- CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
- Treatment of Type I Diabetes by Islet Transplantation Into the Gastric Submucosa Study Protocol
- Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney Transplantation
- ESTEROID WITHDRAWAL STUDY, SAFETY AND EFFICACY IN RENAL TRANPLANTATION
- ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors
- Stem Cell Transplantation for Stiff Person Syndrome (SPS)
- Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia
- ATG-GCSF in New Onset Type 1 Diabetes
- Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients
- HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- Regimen Optimization Study
- Belatacept in Kidney Transplantation of Moderately Sensitized Patients
- Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
- Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
- Single Dose rATG for Renal Allograft Rejection
- Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant
- Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
- Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)
- BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance
- Preemptive Therapy of GVHD
- Comparing Everolimus and Sirolimus in Renal Transplant Recipients
- Thymoglobulin in Cadaver Donor
- Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria
- Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis
- Non-Myeloablative Conditioning and Bone Marrow Transplantation
- Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAA
- Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
- Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation
- Belatacept Early Steroid Withdrawal Trial
- Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
- CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
- Renal Transplantation in the Elderly - nEverOld Study
- Allogeneic Stem Cell Transplant for CLL
- Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies
- Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies
- Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease
- High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
- Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
- Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
- Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
- Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
- Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial
- Scleroderma Treatment With Autologous Transplant (STAT) Study
- Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
- Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
- Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate
- Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients
- Research Study of ATG and Rituximab in Renal Transplantation
- De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction
- Low Dose Thymoglobin in Renal Transplant Patients
- A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease
- Studies of Kidney Transplant Outcome
- A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf
- Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies
- Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
- Thymoglobulin Induction in Kidney Transplant Recipients
- Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia
- Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols
- Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
- A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)
- Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection
- Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia
- Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
- Reversing Type 1 Diabetes After it is Established
- Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
- Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
- Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
- Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
- Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
- Comparison of Tacrolimus and Myfortic Versus Tacrolimus and Sirolimus
- Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation
- Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant
- Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
- Pilot Study of Unrelated Cord Blood Transplantation
- Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin
- Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
- Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
- Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal
- Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML
- Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS)
- Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
- Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)
- Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
- Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
- Comparison of ATG to Thymoglobuline in Renal Transplantation
- Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists
- Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
- Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
- Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
- Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome
- Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
- Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation
- Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
- Hematopoietic Stem Cell Transplant in Devic's Disease
- Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients
- Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma
- Randomized Trial for Mixed Acute Rejection
- Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients
- Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)
- Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status
- Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation
- Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases
- Thymoglobulin: Presence and Affect in the Central Lymphatic Compartment
- Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
- Role of Intraoperative Thymoglobulin in Decreasing Ischemia-Reperfusion Injury in Pediatric Heart Transplant Recipients
- Thymoglobulin in Calcineurin Inhibitor and Steroid Minimization Protocol
- Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
- Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation
- Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk
- Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation
- Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
- Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes
- Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma
- Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML
- Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma
- Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
- Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)
- Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings
- Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant
- Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation
- Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
- Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation
- Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
- Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Rel
- Phase I/II Thymus Transplantation With Immunosuppression #950
- Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
- A Study of Thymoglobulin and Tacrolimus in Liver Transplant
- Improved Induction and Maintenance Immunosuppression in Kidney Transplantation
- Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
- A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
- Myfortic vs. Cellcept in Kidney Transplant Recipients
- Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor
- Study of Antithymocyte Globulin for Treatment of New-onset T1DM
- Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
- Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
- FM 140 vs FM100 Study in Patients With Multiple Myeloma
- Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
- Cord Blood Expansion on Mesenchymal Stem Cells
- MMF vs. AZA for Kidney Transplantation
- Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders
- Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies
- Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome
- Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
- IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
- Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
- Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
- Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA
- A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation
- Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
- Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia
- Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia
- Thymoglobulin (ATG) Dose Finding Study
- Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
- AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS
- Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease
- Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal
- Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant
- Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer
- Belatacept to Prevent Organ Rejection in Kidney Transplant Patients
- Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant
- Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
- Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
- Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma
- Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation
- Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation
- Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
- Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
- High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study
- Hematopoietic Stem Cell Support in Vasculitis
- The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients
- Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
- Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients
- An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.
- Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans
- Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies
- The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation
- Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation
- Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no Steroids
- Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
- Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection
- Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients
- Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
- A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection
- Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
- Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
- Evaluating the Use of Thymoglobulin, Sirolimus, and Donor Bone Marrow With Kidney Transplantation Patients
- Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder
- Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
- Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases
- Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia
- Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants
- Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
Clinical trials list
click for details